Hepatic Disease in Patients With HIV

  • Author: Mark S. Sulkowski, MD (More Info)
  • Editors in Chief: Joseph J. Eron, Jr., MD; Daniel R. Kuritzkes, MD
  • Last Reviewed: 11/13/21 (What's New)

Summary

  • In randomized, controlled trials, the proportion of patients receiving combination ART who have grades 3 or 4 elevations in serum ALT or AST levels range from approximately 2% to 18%[Nuñez 2006]
  • Ritonavir-boosted PIs have not been associated with higher rates of hepatotoxicity
  • Liver enzyme elevations in large registration studies were infrequently symptomatic or dose limiting, and permanent liver injury was a distinctly rare event

Action required

Keywords: Drug-Drug Interactions, Hepatic Complications, Special Populations

©2020 Clinical Care Options, LLC. All Rights Reserved.

The materials published via inPractice® reflect the views of the reviewers or authors of the material, not those of Clinical Care Options, LLC, the accredited provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.